Clinical Trials Browser

Phase 3 × Epstein-Barr Virus Infections × Doxorubicin × Clear all

NCT02631109 2016-08-04

L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

Phase 3 Unknown

Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic